FDA approves terlipressin for treatment of HRS-1 despite concerns

FDA Cardiovascular and Renal Drugs Advisory Committee voted 8-7 to recommend approval of terlipressin for the treatment of hepatorenal syndrome type 1 in patients with cirrhosis.
Terlipressin, developed by Mallinckrodt plc, is an investigational agent that consists of a synthetic, 12-amino-acid peptide analog of vasopressin.
“I voted ‘yes’ albeit with some reservation,” David N. Assis, MD, said during his final remarks. “Currently there is nothing else available or close to effective to give these patients. The benefit vs. risk is a critical issue today and a

Source link

Related posts

Andrographolide attenuates imbalance of gastric vascular homeostasis induced by ethanol through glycolysis pathway


What Is a Hemorrhoidectomy?


A newborn girl with a huge abdominal multicystic tumor


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World